Neil S. Belloff
General Counsel en ACORDA THERAPEUTICS, INC. .
Fortuna: - $ al 31/03/2024
Perfil
Neil S.
Belloff is currently the Secretary & General Counsel at Acorda Therapeutics, Inc. He previously worked as the Senior Corporate Counsel at Celgene Corp.
and as the Executive VP, US Corporate & Securities Counsel at Deutsche Telekom AG.
From 2020 to 2021, he served as the COO, Secretary, EVP & General Counsel at Eloxx Pharmaceuticals, Inc. Mr. Belloff completed his undergraduate studies at Queens College and his graduate studies at New York University.
He also obtained a graduate degree from Quinnipiac University School of Law.
Participaciones conocidas en empresas públicas
| Empresa | Fecha | Número de acciones | Valoración | Fecha de valoración |
|---|---|---|---|---|
| 24/04/2023 | 0 ( -.--% ) | - $ | 31/03/2024 |
Cargos activos de Neil S. Belloff
| Empresas | Cargo | Inicio |
|---|---|---|
| ACORDA THERAPEUTICS, INC. | General Counsel | 08/11/2021 |
Antiguos cargos conocidos de Neil S. Belloff.
| Empresas | Cargo | Fin |
|---|---|---|
| ELOXX PHARMACEUTICALS, INC. | Chief Operating Officer | 25/08/2021 |
| CELGENE | Corporate Officer/Principal | - |
| DEUTSCHE TELEKOM AG | Corporate Officer/Principal | - |
Formación de Neil S. Belloff.
| Queens College | Undergraduate Degree |
| New York University | Graduate Degree |
| Quinnipiac University School of Law | Graduate Degree |
Experiencias
Funciones ocupadas
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Relaciones
Relaciones de 1er grado
Empresas vinculadas al 1er grado
Hombre
Mujer
Administradores
Ejecutivos
Empresas relacionadas
| Empresas cotizadas | 3 |
|---|---|
| DEUTSCHE TELEKOM AG | Communications |
| ACORDA THERAPEUTICS, INC. | Health Technology |
| ELOXX PHARMACEUTICALS, INC. | Health Technology |
| Empresas privadas | 1 |
|---|---|
Celgene Corp.
 Celgene Corp. BiotechnologyHealth Technology Celgene Corp. is an integrated global biopharmaceutical company, which engages in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases. Its primary commercial stage products include Revlimid, Pomalyst, Imnovid, Otezla, Abraxane, and Vidaza. The company was founded by David Stirling and Sol Barer in 1986 and is headquartered in Summit, NJ. | Health Technology |
- Bolsa de valores
- Insiders
- Neil S. Belloff
